The effect of sildenafil on pleural and peritoneal effusions after the TCPC operation

Postoperative Inhaled Nitric Oxide Use and Early Outcomes after Fontan Surgery Completion

A considerable number of patients after the Fontan operation require prolonged hospitalization due to significant perioperative morbidities. The early postoperative morbidity can be attributed to elevated pulmonary vascular resistance. We hypothesized that the postoperative outcomes would improve with the routine use of inhaled nitric oxide (iNO) to decrease pulmonary vascular resistance. From January 2015 to November 2017 (Group 1), 37 patients underwent Fontan operation, and from December 2017 to December 2019 (Group 2), 34 patients underwent Fontan operation. All patients in Group 2 received iNO in the immediate perioperative period as part of a standardized postoperative pathway. There was no statistically significant difference in demographics or single ventricle subtype between the two groups. All patients underwent an extracardiac Fontan, and Group 2 had a higher number of fenestration (p< 0.01). Pre-Fontan hemodynamics showed no statistically significant difference in Glenn pressure, transpulmonary gradient, or systemic arterial and venous saturation. Both groups had a median length of stay of 13 days (p = 0.5), median chest tube placement of 7 days (p = 0.5), and there was no statistically significant difference in major complications. Readmission within 1 month of discharge occurred in five patients in Group 1 and six patients in Group 2 (p = 0.7). Routine use of iNO in the early postoperative period after Fontan operation did not reduce the length of stay, chest tube duration, rate of complications, or readmission.

A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD

OBJECTIVES

Complications from pulmonary hypertension are one of the leading contributors to morbidity and mortality post-cardiopulmonary bypass surgery in children with CHD. Pulmonary vasodilator therapies are commonly used post-operatively, but the optimal target patient population, therapy choice, timing of therapy initiation, and duration of therapy are not well defined.

METHODS

We used PubMed and EMBASE to identify studies from 2000 to 2020 investigating the use of pulmonary vasodilator therapy post-cardiopulmonary bypass in children aged 0-18 years. To ensure eligibility criteria, studies were systematically reviewed by two independent reviewers.

RESULTS

We identified 26 studies of 42,971 children across four medication classes; 23 were single centre, 14 were prospective, and 11 involved randomisation (four of which employed a placebo-control arm). A disproportionate number of children were from a single retrospective study of 41,872 patients. Definitions varied, but change in pulmonary haemodynamics was the most common primary outcome, used in 14 studies. Six studies had clinical endpoints, with mortality the primary endpoint for two studies. Treatment with inhaled nitric oxide, iloprost, and sildenafil all resulted in improved haemodynamics in specific cohorts of children with post-operative pulmonary hypertension, although improved outcomes were not consistently demonstrated across all treated children. Iloprost may be a cheaper alternative to inhaled nitric oxide with similar haemodynamic response.

CONCLUSION

Studies were predominantly single-centre, a control arm was rarely used in randomised studies, and haemodynamic endpoints varied significantly. Further research is needed to reduce post-operative morbidity and mortality from pulmonary hypertension in children with CHD.

The Year in Review: Anesthesia for Congenital Heart Disease 2019

This review focuses on the literature published from January 2019 to February 2020 that is of interest to anesthesiologists taking care of children and adults with congenital heart disease. Five themes are addressed during this time period, and 59 peer-reviewed articles are discussed.